Танцевальная терапия как метод реабилитации при ревматических заболеваниях

   A dance is considered from the perspective of art therapy, psychotherapy and kinesiotherapy as a component of therapeutic exercises. Previous experience with dance therapy in various rheumatic diseases is presented, and a theoretical rationale for adapting new dance styles for the purposes of complex non-drug treatment of rheumatologic patients is provided.   Рассмотрено использование танца с позиции арт-терапии, психотерапии и кинезиотерапии как составляющей лечебной физкультуры. Представлен имеющийся опыт танцевальной терапии при различных ревматических заболеваниях, приведено теоретическое обоснование адаптации новых танцевальных стилей для целей комплексного немедикаментозного лечения ревматологических пациентов

INVESTIGATION OF THE METAL MELTING PROCESS

The nonlinear mathematical model of calculation of temperature fields in the process of metal melting is formulated and solved using the method of equivalent source taking into account nonlinearity of thermophysical properties of material and variable terms of heat exchange

ANALYSIS OF THERMAL CONDUCTION AT MELTING OF METAL BRICKS IN LIQUID BATH. MESSAGE 2. MODELING AND CALCULATION OF PROCESS OF THE ALLOYED STEEL BRICKS MELTING IN MODEM MELTING AGGREGATES

The methods of calculation of duration of the metallic bricks heating and melting in liquid bath, taking into account variability of thermal-physical characteristics of metal due to temperature, is developed

Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts

We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in volunteers aged 18–60 and open multi-center comparative phase IIb clinical trial in volunteers aged 60 years and older. The safety of the vaccine was assessed in 400 volunteers in the 18–60 age cohort who received two doses of the vaccine (n = 300) or placebo (n = 100) and in 200 volunteers in 60+ age cohort all of whom received three doses of the vaccine. The studied vaccine has shown good tolerability and safety. No deaths, serious adverse events (AEs), or other significant AEs related to vaccination have been detected. The most common AE in vaccinated participants was pain at the injection site (p p 1:256, the rate of fourfold increase in nAB levels was below 45%; the participants who were seropositive at screening of the 2nd vaccination did not lead to a significant increase in nAB titers. In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with over 85% NT seroconversion rates after complete vaccination course in participants who were seronegative at screening in both age groups: 18–60 and 60+. In participants who were seropositive at screening and had nAB titers below 1:256, a single vaccination led to a fourfold increase in nAB levels in 85.2% of cases. These findings indicate that CoviVac can be successfully used both for primary vaccination in a two-dose regimen and for booster vaccination as a single dose in individuals with reduced neutralizing antibody levels